Released Nov 4, 2025, before the open
10-Q filed Nov 4, 2025, 35 days after period end · 0001785530-25-000031
Q3 2025 · 10-Q
Revenue—
Net Income-$16.37M-$16.37M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.36-$0.36 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$15,726,000N/M
Operating Cash Flowderived-$15,156,000N/M
Free Cash Flowderived-$15,156,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | -$16.37M | -$16.67M | -$8.29M | -$11.94M |
| EPS Diluted | -$0.36 | -$0.38 | -$0.23 | -$0.40 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR